Aurinia Pharmaceuticals Inc. Research and Development Expense
Aurinia Pharmaceuticals Inc. (AUPH) reported Research and Development Expense of $13.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. research and development expense for the quarter ending 2026-06-30 was $13.05M, a 75.59% increase year-over-year.
- Aurinia Pharmaceuticals Inc. research and development expense for the quarter ending 2026-03-31 was $7.47M, a 30.07% increase year-over-year.
- Aurinia Pharmaceuticals Inc. research and development expense for the quarter ending 2025-12-31 was $10.89M, a 34.39% increase year-over-year.
- Aurinia Pharmaceuticals Inc. research and development expense for the quarter ending 2025-09-30 was $8.44M, a 176.83% increase year-over-year.
- Aurinia Pharmaceuticals Inc. research and development expense for fiscal 2025 was $32.51M, a 56.39% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. research and development expense for fiscal 2024 was $20.79M, a 58.13% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. research and development expense for fiscal 2023 was $49.64M, a 10.34% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. research and development expense for fiscal 2022 was $44.99M, a 12.03% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.05M 10-Q · filed 2026-08-06 | $20.52M 10-Q · filed 2026-08-06 | $31.41M derived: sum of 3 quarters · filed 2026-08-06 | $39.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.47M 10-Q · filed 2026-05-07 | $18.36M derived: sum of 2 quarters · filed 2026-05-07 | $26.80M derived: sum of 3 quarters · filed 2026-05-07 | $34.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.33M derived: sum of 2 quarters · filed 2026-02-26 | $26.76M derived: sum of 3 quarters · filed 2026-08-06 | $32.51M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.44M 10-Q · filed 2025-11-04 | $15.87M derived: sum of 2 quarters · filed 2026-08-06 | $21.61M 10-Q · filed 2025-11-04 | $29.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.43M 10-Q · filed 2026-08-06 | $13.18M 10-Q · filed 2026-08-06 | $21.28M derived: sum of 3 quarters · filed 2026-08-06 | $24.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.74M 10-Q · filed 2026-05-07 | $13.85M derived: sum of 2 quarters · filed 2026-05-07 | $16.90M derived: sum of 3 quarters · filed 2026-05-07 | $20.98M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.15M derived: sum of 2 quarters · filed 2026-02-26 | $15.23M derived: sum of 3 quarters · filed 2026-02-26 | $20.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.05M 10-Q · filed 2025-11-04 | $7.13M derived: sum of 2 quarters · filed 2025-11-04 | $12.68M 10-Q · filed 2025-11-04 | $22.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.08M 10-Q · filed 2025-07-31 | $9.63M 10-Q · filed 2025-07-31 | $19.86M derived: sum of 3 quarters · filed 2026-02-26 | $33.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $5.55M 10-Q · filed 2025-05-12 | $15.78M derived: sum of 2 quarters · filed 2026-02-26 | $29.38M derived: sum of 3 quarters · filed 2026-02-26 | $42.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.83M derived: sum of 2 quarters · filed 2026-02-26 | $36.48M derived: sum of 3 quarters · filed 2026-02-26 | $49.64M 10-K · filed 2026-02-26 |
| 2023-09-30 | $13.61M 10-Q · filed 2024-11-07 | $26.25M derived: sum of 2 quarters · filed 2024-11-07 | $39.41M 10-Q · filed 2024-11-07 | $49.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $12.65M 10-Q · filed 2024-08-01 | $25.81M 10-Q · filed 2024-08-01 | $35.68M derived: sum of 3 quarters · filed 2025-02-27 | $46.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $13.16M 10-Q · filed 2024-05-02 | $23.03M derived: sum of 2 quarters · filed 2025-02-27 | $34.00M derived: sum of 3 quarters · filed 2025-02-27 | $45.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $20.84M derived: sum of 2 quarters · filed 2025-02-27 | $32.37M derived: sum of 3 quarters · filed 2025-02-27 | $44.99M 10-K · filed 2025-02-27 |
| 2022-09-30 | $10.97M 10-Q · filed 2023-11-02 | $22.50M derived: sum of 2 quarters · filed 2023-11-02 | $35.12M 10-Q · filed 2023-11-02 | $46.27M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $11.53M 10-Q · filed 2023-08-03 | $24.14M 10-Q · filed 2023-08-03 | $35.29M derived: sum of 3 quarters · filed 2024-02-15 | $55.36M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $12.62M 10-Q · filed 2023-05-04 | $23.77M derived: sum of 2 quarters · filed 2024-02-15 | $43.84M derived: sum of 3 quarters · filed 2024-02-15 | $53.93M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $11.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $31.21M derived: sum of 2 quarters · filed 2024-02-15 | $41.31M derived: sum of 3 quarters · filed 2024-02-15 | $51.14M 10-K · filed 2024-02-15 |
| 2021-09-30 | $20.07M 10-Q · filed 2022-11-03 | $30.16M derived: sum of 2 quarters · filed 2022-11-03 | $39.99M 10-Q · filed 2022-11-03 | $53.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $10.09M 10-Q · filed 2022-08-04 | $19.92M 10-Q · filed 2022-08-04 | $33.10M derived: sum of 3 quarters · filed 2023-02-28 | $45.34M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $9.83M 10-Q · filed 2022-05-10 | $23.01M derived: sum of 2 quarters · filed 2023-02-28 | $35.25M derived: sum of 3 quarters · filed 2023-02-28 | $46.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $13.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $25.42M derived: sum of 2 quarters · filed 2023-02-28 | $36.49M derived: sum of 3 quarters · filed 2023-02-28 | $50.33M 10-K · filed 2023-02-28 |
| 2020-09-30 | $12.24M 10-Q · filed 2021-11-03 | $23.32M derived: sum of 2 quarters · filed 2021-11-03 | $37.15M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $11.08M 10-Q · filed 2021-08-05 | $24.91M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $13.84M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $52.87M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $41.38M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |